TSCAN THERAPEUTICS, INC. Net Income
TSCAN THERAPEUTICS, INC. (TCRX) reported Net Income of -$30.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$30.36M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$28.67M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$22.98M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$35.71M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2025 was -$129.77M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2024 was -$127.50M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$89.22M.
- TSCAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$66.22M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.36M 10-Q · filed 2026-08-12 | -$59.02M 10-Q · filed 2026-08-12 | -$82.00M derived: sum of 3 quarters · filed 2026-08-12 | -$117.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$28.67M 10-Q · filed 2026-05-06 | -$51.64M derived: sum of 2 quarters · filed 2026-05-06 | -$87.35M derived: sum of 3 quarters · filed 2026-05-06 | -$124.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$22.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$58.69M derived: sum of 2 quarters · filed 2026-03-04 | -$95.64M derived: sum of 3 quarters · filed 2026-08-12 | -$129.77M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$35.71M 10-Q · filed 2025-11-12 | -$72.66M derived: sum of 2 quarters · filed 2026-08-12 | -$106.79M 10-Q · filed 2025-11-12 | -$142.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$36.95M 10-Q · filed 2026-08-12 | -$71.08M 10-Q · filed 2026-08-12 | -$106.89M derived: sum of 3 quarters · filed 2026-08-12 | -$136.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$34.13M 10-Q · filed 2026-05-06 | -$69.94M derived: sum of 2 quarters · filed 2026-05-06 | -$99.82M derived: sum of 3 quarters · filed 2026-05-06 | -$131.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$35.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$65.70M derived: sum of 2 quarters · filed 2026-03-04 | -$97.36M derived: sum of 3 quarters · filed 2026-03-04 | -$127.50M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$29.89M 10-Q · filed 2025-11-12 | -$61.55M derived: sum of 2 quarters · filed 2025-11-12 | -$91.69M 10-Q · filed 2025-11-12 | -$111.30M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$31.66M 10-Q · filed 2025-08-12 | -$61.80M 10-Q · filed 2025-08-12 | -$81.42M derived: sum of 3 quarters · filed 2025-08-12 | -$104.41M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$30.14M 10-Q · filed 2025-05-06 | -$49.76M derived: sum of 2 quarters · filed 2025-05-06 | -$72.75M derived: sum of 3 quarters · filed 2025-05-06 | -$96.80M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$19.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$42.61M derived: sum of 2 quarters · filed 2025-03-05 | -$66.66M derived: sum of 3 quarters · filed 2025-03-05 | -$89.22M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$23.00M 10-Q · filed 2024-11-12 | -$47.04M derived: sum of 2 quarters · filed 2024-11-12 | -$69.61M 10-Q · filed 2024-11-12 | -$88.33M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$24.05M 10-Q · filed 2024-08-12 | -$46.61M 10-Q · filed 2024-08-12 | -$65.33M derived: sum of 3 quarters · filed 2024-08-12 | -$81.58M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$22.56M 10-Q · filed 2024-05-13 | -$41.29M derived: sum of 2 quarters · filed 2024-05-13 | -$57.53M derived: sum of 3 quarters · filed 2024-05-13 | -$72.63M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$18.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$34.97M derived: sum of 2 quarters · filed 2024-03-06 | -$50.06M derived: sum of 3 quarters · filed 2024-03-06 | -$66.22M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$16.25M 10-Q · filed 2023-11-09 | -$31.34M derived: sum of 2 quarters · filed 2023-11-09 | -$47.50M 10-Q · filed 2023-11-09 | -$61.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$15.10M 10-Q · filed 2023-08-10 | -$31.25M 10-Q · filed 2023-08-10 | -$45.45M derived: sum of 3 quarters · filed 2023-08-10 | -$61.29M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$16.16M 10-Q · filed 2023-05-10 | -$30.36M derived: sum of 2 quarters · filed 2023-05-10 | -$46.20M derived: sum of 3 quarters · filed 2023-05-10 | -$56.87M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$30.04M derived: sum of 2 quarters · filed 2023-03-08 | -$40.71M derived: sum of 3 quarters · filed 2023-03-08 | -$48.63M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$15.84M 10-Q · filed 2022-11-09 | -$26.51M derived: sum of 2 quarters · filed 2022-11-09 | -$34.42M 10-Q · filed 2022-11-09 | -$42.23M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$10.67M 10-Q · filed 2022-08-10 | -$18.59M 10-Q · filed 2022-08-10 | -$26.39M derived: sum of 3 quarters · filed 2022-08-10 | -$33.56M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$7.91M 10-Q · filed 2022-05-12 | -$15.72M derived: sum of 2 quarters · filed 2022-05-12 | -$22.89M derived: sum of 3 quarters · filed 2022-05-12 | -$28.50M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$14.98M derived: sum of 2 quarters · filed 2022-03-09 | -$20.59M derived: sum of 3 quarters · filed 2022-03-09 | -$26.13M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$7.17M 10-Q · filed 2021-11-10 | -$12.78M derived: sum of 2 quarters · filed 2021-11-10 | -$18.32M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$5.61M 10-Q · filed 2021-08-19 | -$11.15M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |